Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03713957 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

A Phase 2 study of Parkinson Disease, sponsored by Alkahest.

Completed
Registry status
Phase 2
Development phase
79
Enrollment target
20
Study locations

NCT03713957 is a Phase 2 study of Parkinson Disease that has completed, run by Alkahest. The registered enrollment target is 79 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03713957, a Phase 2 study of Parkinson Disease, has completed, sponsored by Alkahest.

COMPLETED
Registry status
Phase 2
Development phase
79 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive impairment.

Conditions Studied

Parkinson Disease

Interventions

  • OTHER Placebo
  • DRUG GRF6021

Study Locations (20)

Florida

  • Moonshine Research Center - Doral
  • Riverside Clinical Research - Edgewater
  • MD Clinical - Hallandale
  • Research Centers of America, LLC - Hollywood
  • Suncoast Research Group, LLC - Miami
  • Qps_Mra, Llc - South Miami

Georgia

  • Atlanta Center for Medical Research - Atlanta
  • NeuroTrials Research Inc. - Atlanta

Michigan

  • Quest Research Institute - Farmington Hills
  • SRI Biosciences - Plymouth

Texas

  • UT Southwestern Medical Center - Dallas
  • Centex Studies, INC. - Houston

Arkansas

  • Clinical Trials, Inc. - Little Rock

Colorado

  • Rocky Mountain Movement Disorders Center - Englewood

Missouri

  • PsychCare Consultants Research - St Louis

North Carolina

  • Wake Research - Raleigh

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2018-11-12
Est. Completion 2020-07-20
Phase Phase 2

Sponsor

Alkahest

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03713957

The ClinicalTrials.gov registry entry for NCT03713957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is Alkahest, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03713957 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Georgia, Michigan.

Frequently Asked Questions

What is clinical trial NCT03713957 about?

NCT03713957 is a clinical study titled "A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment". This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive impairment.

What is the current status of trial NCT03713957?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2018-11-12. Estimated completion is 2020-07-20.

What conditions does trial NCT03713957 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT03713957?

The interventions under investigation include: Placebo (OTHER), GRF6021 (DRUG).

Who is sponsoring clinical trial NCT03713957?

This trial is sponsored by Alkahest, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03713957 being conducted?

This trial has 20 study locations across Arkansas, Colorado, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.